Profile data is unavailable for this security.
About the company
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.
- Revenue in GBP (TTM)19.55bn
- Net income in GBP2.82bn
- Incorporated1992
- Employees76.10k
- LocationAstraZeneca PLC1 Francis Crick AvenueCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 207 304 5000
- Fax+44 207 604 8151
- Websitehttps://www.astrazeneca.com/Home
Mergers & acquisitions
| Acquired company | AZN:LSE since announced | Transaction value |
|---|---|---|
| Alexion Pharmaceuticals Inc | 2.21% | 39.31bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonza Group AG | 3.56bn | 576.16m | 38.89bn | 16.54k | 67.69 | 7.21 | 40.12 | 10.93 | 9.77 | 11.63 | 60.34 | 91.74 | 0.3189 | -- | -- | 272,551.40 | 5.18 | 5.12 | 6.55 | 6.35 | 40.99 | 38.95 | 16.24 | 13.11 | 1.18 | 14.44 | 0.3421 | 33.19 | 7.15 | 3.46 | 12.83 | 21.39 | 29.81 | 5.31 |
| GlaxoSmithKline plc | 32.43bn | 5.26bn | 70.61bn | 94.07k | 13.44 | 4.75 | 11.05 | 2.18 | 1.04 | 1.04 | 6.44 | 2.96 | 0.3992 | 1.73 | 4.32 | 344,726.00 | 7.35 | 6.21 | 11.51 | 10.38 | 67.56 | 68.84 | 18.41 | 12.69 | 0.607 | 9.04 | 0.5552 | 113.09 | 1.02 | 7.35 | 23.77 | -7.35 | 3.33 | 0.00 |
| Sanofi SA | 31.70bn | 10.47bn | 96.20bn | 99.41k | 9.16 | -- | 8.22 | 3.03 | 9.70 | 9.70 | 29.44 | -- | -- | -- | -- | 371,574.90 | -- | 4.98 | -- | 5.97 | 67.58 | 68.13 | 32.55 | 14.73 | -- | 29.88 | -- | 69.80 | -0.6962 | 1.40 | 323.60 | 22.79 | -5.28 | 1.78 |
| Novo Nordisk A/S | 14.64bn | 4.95bn | 105.73bn | 45.16k | 28.07 | 20.07 | 18.73 | 7.22 | 18.41 | 18.41 | 54.48 | 25.75 | 0.9481 | 1.19 | 4.37 | 2,836,907.00 | 32.03 | 35.30 | 64.91 | 67.18 | 83.17 | 84.10 | 33.78 | 33.51 | 0.5904 | -- | 0.1417 | 50.32 | 4.04 | 3.30 | 8.18 | 3.87 | 28.08 | 7.29 |
| AstraZeneca plc | 19.55bn | 2.82bn | 110.01bn | 76.10k | 39.09 | 10.75 | 22.41 | 5.63 | 2.14 | 2.14 | 14.88 | 7.79 | 0.4517 | 1.57 | 4.86 | 256,953.20 | 6.48 | 3.88 | 9.63 | 5.46 | 78.97 | 80.97 | 14.34 | 10.19 | 0.672 | 3.58 | 0.5822 | 141.03 | 9.16 | 1.50 | 139.40 | 2.50 | -1.34 | 0.2156 |
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Dec 2020 | 68.53m | 5.22% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2020 | 56.10m | 4.27% |
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2020 | 54.58m | 4.16% |
| The Vanguard Group, Inc.as of 01 Jun 2021 | 35.25m | 2.69% |
| Norges Bank Investment Managementas of 01 Jun 2021 | 30.24m | 2.30% |
| BlackRock Fund Advisorsas of 01 Jun 2021 | 24.89m | 1.90% |
| BlackRock Advisors (UK) Ltd.as of 01 Jun 2021 | 17.04m | 1.30% |
| SSgA Funds Management, Inc.as of 01 Jun 2021 | 13.58m | 1.04% |
| State Street Global Advisors Ltd.as of 01 Jun 2021 | 12.01m | 0.92% |
| BlackRock Advisors LLCas of 01 Jun 2021 | 11.22m | 0.85% |
